RCKT Stock Analysis: Buy, Sell, or Hold?
RCKT - Rocket Pharmaceuticals, Inc. Common Stock
$3.40
-0.20 (-5.56%)
▼
5d:
-7.36%
30d:
-12.37%
90d:
+4.62%
HOLD
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
RCKT is down 7.4% this week, but smart money is accumulating calls. Top strike: $5 2026-07-17 with 1,758 OI. Call ratio: 98% View Scanner →
Strength: 8.4/10
Get Alerted When RCKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
3 traders called RCKT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RCKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: RCKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: RCKT is currently trading at $3.40, which is considered oversold relative to its 30-day fair value range of $3.48 to $3.77.
Technical Outlook: Technically, RCKT is in a uptrend. The price is currently testing key support at $3.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.30 (+173.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RCKT is in a uptrend. The price is currently testing key support at $3.40. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 5.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $9.30 (+173.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.48 -
$3.77
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.6%)
- BULLISH: Trading 173.4% below Wall St target ($9.30)
- CAUTION: Recommendation downgraded due to -7.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$3.48 -
$3.77
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.40
Resistance Level
$3.96
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.93
Wall Street Target
$9.30
(+173.4%)
Share & Embed Analysis
Last updated: May 15, 2026 6:30 AM ET
Data refreshes hourly during market hours. Next update: 7:30 AM
Data refreshes hourly during market hours. Next update: 7:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RCKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
John Militello
SELL
1157 shares
2026-02-18
Gaurav Shah
SELL
12279 shares
2026-02-13
John Militello
SELL
3726 shares
2026-02-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$550 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$875 | 63 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 60 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 51 HOLD |
